Here we review the evidence for use of biologic agents in the second-line setting and beyond. We also discuss off-label indications for biologics in selected patient populations, as well as biologics currently under development.
In this review, we address specific issues pertaining to AYA patients with colorectal cancer, including evaluation for hereditary colorectal cancer syndromes, clinicopathologic and biologic features unique to AYA patients with colorectal cancer, treatment outcomes, and survivorship.
Here we discuss the evolution of standard therapy for rectal cancer patients and the use of preoperative CRT for the treatment of locally advanced disease. Treatment schemes that have attempted to broaden the horizons of standard therapy include the use of induction chemotherapy and “watch-and-wait” approaches.
By clicking Accept, you agree to become a member of the UBM Medica Community.